(News Bulletin 247) – Invest Securities confirms its buy rating on Transgene shares, with an unchanged price target of 5.4 euros.
‘Benefiting from very wide media coverage since this weekend, Transgene saw its stock jump by +22% yesterday (and +40% at the peak) following the presentation of updated data from its personalized cancer vaccine. head and neck on the occasion of the ASCO congress’, underlines the analyst.
The results seem ‘very promising’ as to the therapeutic potential of this vaccine.
‘Biologically, the results remain consistent with the demonstration of a strong specific immune response induced by the vaccine, and a correlation with the observed clinical benefit’, concludes the broker.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
